Skip to content

Effects of remimazolam on hemodynamics in children with congenital heart disease

Effects of remimazolam on hemodynamics in children with congenital heart disease

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400084993
Enrollment
Unknown
Registered
2024-05-29
Start date
2024-06-05
Completion date
Unknown
Last updated
2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

congenital heart disease

Interventions

case series:none

Sponsors

Shanghai Children’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age <18 years, American Society of Anesthesiologists (ASA) physical status II or III, and elective cardiac catheterization procedures under general anesthesia.

Exclusion criteria

Exclusion criteria: Exclusion criteria: previous history of surgery; preoperative hepatic or renal dysfunction or other systemic complications; patients withdrew on their own; withdrawal ordered by the investigator (occurrence of serious adverse events, etc.).

Design outcomes

Primary

MeasureTime frame
Changes in pulmonary vascular resistance before and after remazolam administration;

Secondary

MeasureTime frame
heart rate;SPO2;cardiac output;cardiac index;

Countries

China

Contacts

Public ContactWei Rong

Department of Anesthesiology, Shanghai Children’s Hospital

weirongej@163.com+86 138 0166 2704

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026